IRIDEX Corporation — FY2022 Form 10-K
Business context and period. Iridex develops and sells ophthalmic laser systems, delivery devices and disposable probes for glaucoma and retinal diseases. Its MicroPulse and Endpoint Management technologies are key offerings; recurring revenue comes from consumables, service and support. Fiscal 2022 ended December 31, 2022, and the comparable 2021 fiscal year ended January 1, 2022; each included 52 weeks. Amounts below are in U.S. dollars.
Financial performance and liquidity
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue | $57.0 million | $53.9 million |
| Gross profit / margin | $25.4 million / 44.5% | $22.8 million / 42.4% |
| Operating expenses | $32.9 million | $30.4 million |
| Operating loss | $7.5 million | $7.5 million |
| Net loss | $7.5 million | $5.2 million |
| Net loss per share, basic and diluted | $0.47 | $0.34 |
| Cash from (used in) operating activities | $(9.5) million | $8.2 million |
- Revenue rose 5.7%. Cyclo G6 revenue increased 5.3% to $14.7 million; retina revenue rose 1.8% to $31.7 million; other revenue increased 20.1% to $10.6 million.
- Gross margin improved 2.1 percentage points, which management attributed mainly to favorable product mix and higher-margin exclusive distribution fees.
- Sales and marketing expense increased 24.2% to $18.2 million, primarily from higher headcount, travel, commissions and product-launch marketing. R&D expense rose 4.5% to $7.2 million; general and administrative expense declined 14.7% to $7.6 million.
- Other income fell to $0.06 million from $2.35 million; FY2021 included a $2.5 million gain from forgiveness of a Paycheck Protection Program loan.
- Cash and cash equivalents were $13.9 million, down from $23.9 million; working capital was $23.3 million, down from $29.6 million. The company used $9.5 million in operating cash, including approximately $3.5 million invested in inventory and prepaid materials to mitigate supply constraints.
- No amounts were outstanding on the secured revolving credit facility, which provided for up to $8.0 million and was extended through December 1, 2023. Total liabilities were $25.1 million; the filing does not identify borrowings outstanding under the facility at year-end.
Material changes and management commentary
- U.S. revenue increased to $29.2 million from $24.9 million, while international revenue was $27.8 million, or 48.8% of total revenue. International sales declined in some markets, partly offsetting domestic growth.
- Topcon generated $15.9 million, or 28% of revenue, compared with $11.1 million, or 21%, in FY2021. Topcon held 10.1% of Iridex’s voting interest and accounted for 37% of year-end receivables.
- Management said demand and its outlook had improved, but hospital, surgical-center and physician-office capital spending remained subject to uncertainty. It expected continued operating losses and negative operating cash flows, while stating that existing cash should cover anticipated needs for at least 12 months.
- Management cited the expected unwind during 2023 of inventory and prepaid-material purchases made to mitigate supply constraints. No numerical revenue or profitability guidance was provided.
Risks, contingencies and unusual items
- Key risks include persistent losses and cash use, macroeconomic and foreign-exchange pressures, elective-procedure and capital-spending uncertainty, competition, and reliance on international channels and Topcon. The company also relies on sole- or limited-source suppliers and third-party component manufacturers.
- Topcon’s exclusive distribution rights cover certain regions outside the United States. Iridex recognized $1.3 million of related revenue in FY2022; the arrangement’s estimated fair value was approximately $14.8 million and is recognized over time. Topcon’s importance as customer and distributor creates concentration risk.
- Inventory increased to $10.6 million from $7.6 million. Inventory valuation was identified as a critical audit matter because estimates depend on forecasts of demand, product life cycles and other assumptions.
- Future minimum purchase commitments were approximately $20.6 million through FY2024, including $2.1 million for the next 12 months. Operating lease commitments were $1.8 million; the Mountain View facility lease runs through August 2024.
- The company’s TruFocus LIO Premiere voluntary recall termination request remained pending. Iridex disclosed no material legal proceedings and said ordinary-course matters were not expected to materially affect its financial position or results.
- EU Medical Device Regulation transition deadlines were extended, according to the filing, from 2024 to 2028 for its products; Iridex said it would obtain required certification before the transition deadline. Regulatory compliance, reimbursement and product-liability risks remain material.
- Management reported effective disclosure controls and internal control over financial reporting at year-end. The auditor issued an unqualified opinion on the financial statements; it was not engaged to attest to internal-control effectiveness.
Important facts for investors to verify
- Whether cash burn moderates as inventory and prepaid materials unwind, and whether the stated 12-month liquidity expectation remains supportable.
- Whether revenue growth and gross-margin improvement continue without relying disproportionately on Topcon-related sales and distribution-fee revenue.
- Inventory demand, obsolescence reserves and the timing of conversion of elevated inventory into sales and cash.
- Topcon’s sales performance, receivable collection, exclusivity arrangements and regional regulatory approvals.
- Progress on product and EU regulatory requirements, including the pending TruFocus LIO recall termination request.